SUBSCRIBE
SUBSCRIBE
News   FDA

Akorn-Strides, LLC Announces FDA Approval for Rifampin for Injection USP, 600 mg/Vial

May 23, 2008 | 
1 min read
BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Akorn-Strides, LLC today announced the approval of an ANDA for Rifampin for Injection USP, 600 mg/vial. This is the first lyophilized Injectable product approval for the Joint Venture.
FDA Approvals
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Silhouettes of birds circling in the sky
Bankruptcy
Lilly, Astellas circle Sangamo assets as biotech files for bankruptcy
June 23, 2026
 · 
3 min read
 · 
Gabrielle Masson
USA and China trade war. US of America and chinese flags crashed containers on sky at sunset background. 3d illustration
Policy
HHS debuts ‘unprecedented’ initiative to ‘restore American leadership’ in clinical trials
June 22, 2026
 · 
3 min read
 · 
Heather McKenzie
train Pacific Surfliner Train from San Luis Obispo to San Diego.
FDA
REGENXBIO to resubmit application for Hunter gene therapy after FDA’s most recent pivot
June 22, 2026
 · 
3 min read
 · 
Heather McKenzie
Car silhouette in speed motion lines in vector
FDA
Denali sells FDA voucher for $195M to support neurodegenerative pipeline
June 19, 2026
 · 
1 min read
 · 
Annalee Armstrong